PH Roundtable: Conundrums and Controversies in PH-ILD: To Treat or Not to Treat—Identifying Optimal Treatment Candidates

Abstract

This fall, Jeffrey Edelman, MD, Associate Professor of Medicine at the University of Washington and at the VA Medical Center in Seattle, Washington, gathered with Jean Elwing, MD, Professor of Medicine and the Director of the Pulmonary Hypertension Program at the University of Cincinnati; Anjali Vaidya, MD, Associate Professor of Medicine and Co-Director of the Pulmonary Hypertension, Right Heart Failure & CTEPH Program at Temple University in Philadelphia; and Steve Mathai, MD, Associate Professor of Medicine at Johns Hopkins School of Medicine and Co-Director of the Ann Dana Kusch Multidisciplinary Research Program for Pulmonary Hypertension and Interstitial Lung Disease, to discuss pulmonary hypertension (PH) in World Health Organization (WHO) Group 3 patients with interstitial lung disease (ILD).